Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic hexapeptide growth hormone secretagogue receptor agonist
An experimental peptide that can make the body release growth hormone.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Several small peer-reviewed human pharmacology and endocrine studies consistently demonstrate acute exposure and GH release.
The response depends partly on endogenous GHRH physiology.
A nine-person IV study estimated an elimination half-life around 2.5 hours.
The study did not establish improved growth outcomes.
A small study found route-dependent hormone and EEG changes, not durable sleep benefit.
The record is limited to small physiology studies.
Risks & unknowns
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryNot FDA approved — small acute human physiology studies Long-term benefit and safety, appetite and metabolic effects, endocrine nonselectivity, desensitization, product quality, and any body-composition, recovery, or sleep outcome.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
Nine healthy men were studied on two occasions, with saline or a GHRH antagonist before GHRP-6.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| Acute laboratory sessions | 1 microgram/kg | Single challenge per study occasion |
The experiment measured hormone responses. It does not establish a repeated subcutaneous regimen or a clinical benefit.
GHRP-6 · endogenous GHRH blockade experiment Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A peer-reviewed early human study administered GHRP-6 to healthy men to characterize short-term exposure and elimination.
Population: Nine healthy men
Design: Open-label intravenous pharmacokinetic study
Mechanisms
GHRP-6 is a synthetic hexapeptide agonist at GHSR1a. Human studies show rapid pharmacokinetics and acute GH release, including oral challenge research in children with short stature. Blocking endogenous GHRH markedly reduces its GH response, demonstrating dependence on intact hypothalamic-pituitary physiology. Nocturnal experiments found route-dependent GH, ACTH, cortisol, and sleep-EEG effects rather than a clear sleep benefit. No FDA-approved product, modern long-term outcomes program, or controlled body-composition benefit was identified.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
PK, endocrine, and nocturnal physiology have been studied.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Confidence is low for untested therapeutic outcomes.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study included nine healthy men and measured pharmacokinetics rather than a clinical outcome. Intravenous single-exposure findings do not establish chronic subcutaneous use, therapeutic benefit, or product equivalence. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Placebo-controlled nocturnal administration study
Healthy volunteers
GHRP-6 altered endocrine measures and sleep architecture in a route-dependent manner without demonstrating a simple sleep benefit.
Study administration: GHRP-6 by different routes or placebo
Limitations: Small one-night studies cannot define chronic sleep effects.
Controlled blockade study
Healthy adults
Blocking endogenous GHRH markedly reduced the response to GHRP-6.
Study administration: GHRP-6 with or without endogenous GHRH blockade
Limitations: Acute physiology does not establish clinical outcomes.
Open-label intravenous pharmacokinetic study
Nine healthy men
GHRP-6 showed rapid distribution and an estimated terminal elimination half-life around 2.5 hours.
Study administration: Intravenous GHRP-6
Limitations: Nine participants and intravenous exposure do not establish chronic subcutaneous outcomes or product equivalence.
Acute oral challenge study
Children with short stature
Oral GHRP-6 elicited acute GH responses in the studied children.
Study administration: Oral GHRP-6
Limitations: Hormone release does not establish improved linear growth or long-term safety.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2013-01-01 · PMID 23099431 · DOI 10.1016/j.ejps.2012.10.006
1999-05-01 · PMID 10336729 · DOI 10.1046/j.1365-2826.1999.00364.x
1998-04-01 · PMID 9543138 · DOI 10.1210/jcem.83.4.4711
1995-11-01 · PMID 7581965 · DOI 10.1530/eje.0.1330425